EGFR exon 20 insertion mutation
1 drugsPredictive biomarker for patient selection in 1 indication
1
Approved Drugs
1
Indications
1
Companies
EGFR exon 20 insertion mutation is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 1 indication including Non-Small Cell Lung Cancer. Explore the targeted therapies, indications, testing methods, and companies developing EGFR exon 20 insertion mutation drugs below.
Search EGFR exon 20 insertion mutation Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting EGFR exon 20 insertion mutation
| Drug | Company | Therapeutic Area |
|---|---|---|
| RYBREVANT FASPRO | Johnson & Johnson | Oncology |